

(sending institution please stamp here:)

patient label  
name, date of birth, address

phone: ( \_\_\_\_\_ ) \_\_\_\_\_ - \_\_\_\_\_ extension please

GHSG Studienzentrale  
Uniklinik Köln

50924 Köln  
Germany

phone: +49 221 / 478-88166  
fax: +49 221 / 478-88188

### INCLUSION CRITERIA

# IN

date of histological findings

day	month	year

**Trial: AVD-Rev**

**Case ID: CRF ID:**

#### Inclusion criteria:

- |  | yes                      | no                       |
|--|--------------------------|--------------------------|
| 1. Written informed consent  | <input type="checkbox"/> | <input type="checkbox"/> |
| 2. Age $\geq 60$ and $\leq 75$ years at the time of signing the informed consent form  | <input type="checkbox"/> | <input type="checkbox"/> |
| 3. Ability to adhere to the study visit schedule and other protocol requirements   | <input type="checkbox"/> | <input type="checkbox"/> |
| 4. Previously untreated, histologically proven classical Hodgkin Lymphoma, intermediate or advanced stage (CS I + II with one or more risk factors, CS III + IV) Biopsy material must be reviewed centrally by at least one member of a panel of HL pathology experts  | <input type="checkbox"/> | <input type="checkbox"/> |
| 5. ECOG performance status of $\leq 2$ at study entry  | <input type="checkbox"/> | <input type="checkbox"/> |
| 6. Laboratory test results within these ranges:<br>- WBC $\geq 2.500/\mu\text{l}$ , neutrophils $\geq 1.000/\mu\text{l}$ , platelets $\geq 100.000/\mu\text{l}$<br>(unless blood count disorders due to HL - then neutrophils $\geq 500/\mu\text{l}$ and platelets $\geq 50.000/\mu\text{l}$ are allowed)<br>- Alkaline phosphatase $\leq 2$ ULN<br>- AST or ALT $\leq 2$ ULN or 5x ULN if hepatic involvement of HL<br>- Serum total bilirubin $\leq 2$ ULN (unless with Gilbert's syndrome)<br>- HBA1c $\leq 7,5\%$<br>- Creatinin clearance $\geq 60\text{ml/ min}$ | <input type="checkbox"/> | <input type="checkbox"/> |
| 7. Females of childbearing potential (FCBP) and sexually active males must agree to use reliable contraception as outlined in section 17.7.  | <input type="checkbox"/> | <input type="checkbox"/> |
| 8. Disease free of prior malignancies for $\geq 5$ years with exception of currently treated basal cell or squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast   | <input type="checkbox"/> | <input type="checkbox"/> |
| 9. Ability to take aspirin (100mg) daily as prophylactic anticoagulation, (patients intolerant to ASA may use low molecular weight heparin)  | <input type="checkbox"/> | <input type="checkbox"/> |
| 10. No major organ dysfunction   | <input type="checkbox"/> | <input type="checkbox"/> |

day	month	year

Investigator signature